Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

Brown, Todd T; Moser, Carlee; Currier, Judith S; Ribaudo, Heather J; Rothenberg, Jennifer; Kelesidis, Theodoros; Yang, Otto; Dubé, Michael P; Murphy, Robert L; Stein, James H; McComsey, Grace A

doi:10.1093/infdis/jiaa027

In “Changes in Bone Mineral Density after Antiretroviral Initiation with Tenofovir Disoproxil Fumarate-Emtricitabine plus Atazanavir-Ritonavir, Darunavir-Ritonavir, or Raltegravir [J Infect Dis. 2015 Oct 15;212(8):1241–9.] by Brown et al. there are three errors noted by the authors:

Lines 176–180 Corrected sentence should read:

The following monocyte cell phenotypes were characterized and expressed as percentages: classical phenotype (CD14+CD16-), intermediate phenotype (CD14+CD16+), non-classical phenotype (CD14dimCD16+). CD4+ and CD8+ T cells with activated (HLA-DR+CD38+), senescent (CD28-CD57+) or senescent and exhausted (CD28-CD57+PD1+) phenotypes were assessed.

Lines 279–282 Corrected sentence should read:

Associations of monocyte subpopulations (% MNC: CD14+CD16+, % MNC: CD14dimCD16+) with bone loss at either the lumbar spine or the total hip or were also not consistently detected (data not shown).

Table 1:

Table 1.

Open in new tab

Subject Characteristics at Baseline

	ATV/r (n=109)	RAL (n=106)	DRV/r (n=113)
Age (y)	37 (31,45)	36 (27,44)	35 (27,46)
Sex	91% M, 9% F	89% M,11% F	89% M,11% F
Race/ethnicity†	49% W, 31% B, 18% H	41% W, 32% B, 19% H	42% W, 33% B, 22% H
Weight (kg)	80 (69,88)	77 (66,89)	77(67,83)
Body Mass Index (kg/m²)	26 (23, 29)	24 (22,28)	24 (22, 27)
Concomitant Medications affecting Bone*	22%	22%	20%
Current Smoking	40%	37%	36%
CD4+ cell count (/mm³)	350 (211, 461)	343 (207,461)	355(207, 461)
HIV-1 RNA (log₁₀c/mL)	4.62 (4.05, 5.10)	4.52 (4.13, 5.08)	4.52 (3.95, 4.95)
hsCRP (mg/L)	1.45 (0.71, 3.16)	1.35 (0.69, 2.8)	1.17 (0.66, 2.95)
IL-6 (pg/mL)	1.82 (1.20, 2.69)	1.55 (1.07, 3.02)	1.78 (1.20, 2.75)
sIL-2R (pg/ml)	1862 (1479, 2291)	1820 (1202, 2344)	1660 (1202, 2239)
sCD14 (ng/ml)	1778 (1413, 2138)	1698 (1445, 1950)	1660 (1445, 2042)
sCD163 (ng/ml)	1148 (813, 1585)	1230 (832, 1585)	1023 (741, 1548)
OPG (pmol/L)	3.89 (3.16, 4.90)	3.98 (3.31, 4.68)	4.47 (3.63, 5.25)
RANK L (pg/ml)	35.5 (16.9, 58.9)	26.9 (11.2, 53.7)	24.5 (11.2, 49.0)
	N=101	N=95	N=101
% CD4(+): CD28(-) CD57(+)	4.8 (2.2, 9.9)	5.2 (2.0, 11.3)	5.3 (2.6, 9.3)
% CD4(+): CD28(-) CD57(+) PD1(+)	0.03 (0.01, 0.07)	0.03 (0.01, 0.07)	0.03 (0.01, 0.06)
% CD8(+): CD28(-) CD57(+)	23.0 (16.9, 30.5)	25.9 (18.6, 30.9)	22.9 (18.4, 30.5)
% CD8(+): CD28(-) CD57(+) PD1(+)	0.07 (0.05, 0.12)	0.08 (0.05, 0.16)	0.09 (0.04, 0.14)
% CD4(+): CD38(+) HLADR(+)	19.0 (11.9, 30.3)	19.4 (12.0, 32.2)	17.4 (10.3, 26.3)
% CD8(+): CD38(+) HLADR(+)	41.7 (34.8, 55.2)	44.7 (37.0, 53.7)	42.5 (33.2, 53.2)
% MNC: CD14dimCD16+	0.7 (0.4, 1.7)	0.7 (0.2, 1.9)	0.9 (0.3, 1.6)
% MNC: CD14+CD16+	9.7 (5.9, 13.8)	9.7 (5.0, 13.1)	9.0 (5.7, 11.7)

	ATV/r (n=109)	RAL (n=106)	DRV/r (n=113)
Age (y)	37 (31,45)	36 (27,44)	35 (27,46)
Sex	91% M, 9% F	89% M,11% F	89% M,11% F
Race/ethnicity†	49% W, 31% B, 18% H	41% W, 32% B, 19% H	42% W, 33% B, 22% H
Weight (kg)	80 (69,88)	77 (66,89)	77(67,83)
Body Mass Index (kg/m²)	26 (23, 29)	24 (22,28)	24 (22, 27)
Concomitant Medications affecting Bone*	22%	22%	20%
Current Smoking	40%	37%	36%
CD4+ cell count (/mm³)	350 (211, 461)	343 (207,461)	355(207, 461)
HIV-1 RNA (log₁₀c/mL)	4.62 (4.05, 5.10)	4.52 (4.13, 5.08)	4.52 (3.95, 4.95)
hsCRP (mg/L)	1.45 (0.71, 3.16)	1.35 (0.69, 2.8)	1.17 (0.66, 2.95)
IL-6 (pg/mL)	1.82 (1.20, 2.69)	1.55 (1.07, 3.02)	1.78 (1.20, 2.75)
sIL-2R (pg/ml)	1862 (1479, 2291)	1820 (1202, 2344)	1660 (1202, 2239)
sCD14 (ng/ml)	1778 (1413, 2138)	1698 (1445, 1950)	1660 (1445, 2042)
sCD163 (ng/ml)	1148 (813, 1585)	1230 (832, 1585)	1023 (741, 1548)
OPG (pmol/L)	3.89 (3.16, 4.90)	3.98 (3.31, 4.68)	4.47 (3.63, 5.25)
RANK L (pg/ml)	35.5 (16.9, 58.9)	26.9 (11.2, 53.7)	24.5 (11.2, 49.0)
	N=101	N=95	N=101
% CD4(+): CD28(-) CD57(+)	4.8 (2.2, 9.9)	5.2 (2.0, 11.3)	5.3 (2.6, 9.3)
% CD4(+): CD28(-) CD57(+) PD1(+)	0.03 (0.01, 0.07)	0.03 (0.01, 0.07)	0.03 (0.01, 0.06)
% CD8(+): CD28(-) CD57(+)	23.0 (16.9, 30.5)	25.9 (18.6, 30.9)	22.9 (18.4, 30.5)
% CD8(+): CD28(-) CD57(+) PD1(+)	0.07 (0.05, 0.12)	0.08 (0.05, 0.16)	0.09 (0.04, 0.14)
% CD4(+): CD38(+) HLADR(+)	19.0 (11.9, 30.3)	19.4 (12.0, 32.2)	17.4 (10.3, 26.3)
% CD8(+): CD38(+) HLADR(+)	41.7 (34.8, 55.2)	44.7 (37.0, 53.7)	42.5 (33.2, 53.2)
% MNC: CD14dimCD16+	0.7 (0.4, 1.7)	0.7 (0.2, 1.9)	0.9 (0.3, 1.6)
% MNC: CD14+CD16+	9.7 (5.9, 13.8)	9.7 (5.0, 13.1)	9.0 (5.7, 11.7)

Values represent median (Q1,Q3) or percent; † W: white; B: black; H:hispanic; remaining represents other

*includes androgen, anticonvulsants, proton pump inhibitors, corticosteroids, estrogens, SSRIs

Table 1.

Open in new tab

Subject Characteristics at Baseline

	ATV/r (n=109)	RAL (n=106)	DRV/r (n=113)
Age (y)	37 (31,45)	36 (27,44)	35 (27,46)
Sex	91% M, 9% F	89% M,11% F	89% M,11% F
Race/ethnicity†	49% W, 31% B, 18% H	41% W, 32% B, 19% H	42% W, 33% B, 22% H
Weight (kg)	80 (69,88)	77 (66,89)	77(67,83)
Body Mass Index (kg/m²)	26 (23, 29)	24 (22,28)	24 (22, 27)
Concomitant Medications affecting Bone*	22%	22%	20%
Current Smoking	40%	37%	36%
CD4+ cell count (/mm³)	350 (211, 461)	343 (207,461)	355(207, 461)
HIV-1 RNA (log₁₀c/mL)	4.62 (4.05, 5.10)	4.52 (4.13, 5.08)	4.52 (3.95, 4.95)
hsCRP (mg/L)	1.45 (0.71, 3.16)	1.35 (0.69, 2.8)	1.17 (0.66, 2.95)
IL-6 (pg/mL)	1.82 (1.20, 2.69)	1.55 (1.07, 3.02)	1.78 (1.20, 2.75)
sIL-2R (pg/ml)	1862 (1479, 2291)	1820 (1202, 2344)	1660 (1202, 2239)
sCD14 (ng/ml)	1778 (1413, 2138)	1698 (1445, 1950)	1660 (1445, 2042)
sCD163 (ng/ml)	1148 (813, 1585)	1230 (832, 1585)	1023 (741, 1548)
OPG (pmol/L)	3.89 (3.16, 4.90)	3.98 (3.31, 4.68)	4.47 (3.63, 5.25)
RANK L (pg/ml)	35.5 (16.9, 58.9)	26.9 (11.2, 53.7)	24.5 (11.2, 49.0)
	N=101	N=95	N=101
% CD4(+): CD28(-) CD57(+)	4.8 (2.2, 9.9)	5.2 (2.0, 11.3)	5.3 (2.6, 9.3)
% CD4(+): CD28(-) CD57(+) PD1(+)	0.03 (0.01, 0.07)	0.03 (0.01, 0.07)	0.03 (0.01, 0.06)
% CD8(+): CD28(-) CD57(+)	23.0 (16.9, 30.5)	25.9 (18.6, 30.9)	22.9 (18.4, 30.5)
% CD8(+): CD28(-) CD57(+) PD1(+)	0.07 (0.05, 0.12)	0.08 (0.05, 0.16)	0.09 (0.04, 0.14)
% CD4(+): CD38(+) HLADR(+)	19.0 (11.9, 30.3)	19.4 (12.0, 32.2)	17.4 (10.3, 26.3)
% CD8(+): CD38(+) HLADR(+)	41.7 (34.8, 55.2)	44.7 (37.0, 53.7)	42.5 (33.2, 53.2)
% MNC: CD14dimCD16+	0.7 (0.4, 1.7)	0.7 (0.2, 1.9)	0.9 (0.3, 1.6)
% MNC: CD14+CD16+	9.7 (5.9, 13.8)	9.7 (5.0, 13.1)	9.0 (5.7, 11.7)

	ATV/r (n=109)	RAL (n=106)	DRV/r (n=113)
Age (y)	37 (31,45)	36 (27,44)	35 (27,46)
Sex	91% M, 9% F	89% M,11% F	89% M,11% F
Race/ethnicity†	49% W, 31% B, 18% H	41% W, 32% B, 19% H	42% W, 33% B, 22% H
Weight (kg)	80 (69,88)	77 (66,89)	77(67,83)
Body Mass Index (kg/m²)	26 (23, 29)	24 (22,28)	24 (22, 27)
Concomitant Medications affecting Bone*	22%	22%	20%
Current Smoking	40%	37%	36%
CD4+ cell count (/mm³)	350 (211, 461)	343 (207,461)	355(207, 461)
HIV-1 RNA (log₁₀c/mL)	4.62 (4.05, 5.10)	4.52 (4.13, 5.08)	4.52 (3.95, 4.95)
hsCRP (mg/L)	1.45 (0.71, 3.16)	1.35 (0.69, 2.8)	1.17 (0.66, 2.95)
IL-6 (pg/mL)	1.82 (1.20, 2.69)	1.55 (1.07, 3.02)	1.78 (1.20, 2.75)
sIL-2R (pg/ml)	1862 (1479, 2291)	1820 (1202, 2344)	1660 (1202, 2239)
sCD14 (ng/ml)	1778 (1413, 2138)	1698 (1445, 1950)	1660 (1445, 2042)
sCD163 (ng/ml)	1148 (813, 1585)	1230 (832, 1585)	1023 (741, 1548)
OPG (pmol/L)	3.89 (3.16, 4.90)	3.98 (3.31, 4.68)	4.47 (3.63, 5.25)
RANK L (pg/ml)	35.5 (16.9, 58.9)	26.9 (11.2, 53.7)	24.5 (11.2, 49.0)
	N=101	N=95	N=101
% CD4(+): CD28(-) CD57(+)	4.8 (2.2, 9.9)	5.2 (2.0, 11.3)	5.3 (2.6, 9.3)
% CD4(+): CD28(-) CD57(+) PD1(+)	0.03 (0.01, 0.07)	0.03 (0.01, 0.07)	0.03 (0.01, 0.06)
% CD8(+): CD28(-) CD57(+)	23.0 (16.9, 30.5)	25.9 (18.6, 30.9)	22.9 (18.4, 30.5)
% CD8(+): CD28(-) CD57(+) PD1(+)	0.07 (0.05, 0.12)	0.08 (0.05, 0.16)	0.09 (0.04, 0.14)
% CD4(+): CD38(+) HLADR(+)	19.0 (11.9, 30.3)	19.4 (12.0, 32.2)	17.4 (10.3, 26.3)
% CD8(+): CD38(+) HLADR(+)	41.7 (34.8, 55.2)	44.7 (37.0, 53.7)	42.5 (33.2, 53.2)
% MNC: CD14dimCD16+	0.7 (0.4, 1.7)	0.7 (0.2, 1.9)	0.9 (0.3, 1.6)
% MNC: CD14+CD16+	9.7 (5.9, 13.8)	9.7 (5.0, 13.1)	9.0 (5.7, 11.7)

Values represent median (Q1,Q3) or percent; † W: white; B: black; H:hispanic; remaining represents other

*includes androgen, anticonvulsants, proton pump inhibitors, corticosteroids, estrogens, SSRIs

Deleted the 2 rows that show data related to: % MNC: CD14 (hi) CD16 (hi) and % MNC: CD14 (low)CD16 (hi). Replaced with 2 new rows that show data related to: % MNC: CD14dimCD16+ and % MNC: CD14+CD16+. The corrected table is reproduced below.

The authors regret these errors.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Download all slides

Month:	Total Views:
February 2020	46
March 2020	19
April 2020	8
May 2020	2
June 2020	20
July 2020	27
August 2020	22
September 2020	22
October 2020	9
November 2020	25
December 2020	12
January 2021	19
February 2021	12
March 2021	11
April 2021	15
May 2021	7
June 2021	6
July 2021	5
August 2021	10
September 2021	5
October 2021	5
November 2021	8
December 2021	5
January 2022	14
February 2022	15
March 2022	5
April 2022	5
May 2022	5
June 2022	5
July 2022	13
August 2022	9
September 2022	8
October 2022	17
November 2022	7
December 2022	12
January 2023	7
February 2023	19
March 2023	15
April 2023	6
May 2023	2
June 2023	24
July 2023	1
August 2023	6
September 2023	8
October 2023	4
November 2023	8
December 2023	8
January 2024	5
February 2024	6
March 2024	5
April 2024	11
May 2024	15
June 2024	10
July 2024	19
August 2024	12
September 2024	13
October 2024	7
November 2024	6
December 2024	2
January 2025	4
February 2025	2
March 2025	11
April 2025	6

Article Contents

Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

Citations

Views

Altmetric

Email alerts

Citing articles via

Latest

Most Read

Most Cited

Looking for your next opportunity?

Article Contents

Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir

Citations

Views

Altmetric

Email alerts

Citing articles via

Latest

Most Read

Most Cited

Looking for your next opportunity?

This Feature Is Available To Subscribers Only